11 completed, 4 terminated, 3 recruiting, 3 withdrawn. 9 Phase 2, 4 Not applicable, 2 Phase 1, 2 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Recruiting 3, Terminated 1, Withdrawn 1 |
| Not applicable | 4 | Completed 3, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 2 | Terminated 2 |
Follow tesamorelin: new trials by email Literature Review of tesamorelin trials Research Report on tesamorelin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) Tesamorelin, Placebo, Standardized lifestyle counseling - Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Recruiting | Hudson Biotech | 120 | 2026-02-02 | 2026-03-19 |
| Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV Tesamorelin, Placebo, Exercise - HIV-1-infection, Frailty | Phase 2 | Recruiting | Massachusetts General Hospital | 100 | 2025-07-10 | 2026-05-19 |
| Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk Tesamorelin, Identical Placebo - Non-Alcoholic Fatty Liver Disease, Obesity | Phase 2 | Completed | Massachusetts General Hospital | 51 | 2019-01-17 | 2025-11-20 |
| Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury Tesamorelin 2 Milligrams (MG) - Peripheral Nerve Injuries | Phase 2 | Recruiting | Johns Hopkins University | 36 | 2018-06-01 | 2025-11-12 |
| Body Composition and Adipose Tissue in HIV Tesamorelin - HIV Lipodystrophy Syndrome, Growth Hormone Deficiency | Phase 4 | Terminated | Columbia University | 6 | 2018-02-07 | 2026-05-19 |
| The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment Growth Hormone Releasing Hormone (GHRH), Placebo Growth Hormone Releasing Hormone - Mild Cognitive Impairment | Phase 1 | Completed | The University of Texas Medical Branch, Galveston | 22 | 2017-07-18 | 2019-11-04 |
| Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons Tesamorelin - Mild Cognitive Impairment | Phase 2 | Completed | University of California, San Diego | 73 | 2017-02-15 | 2026-03-12 |
| Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia Tesamorelin, Placebo - Sleep Disorder, Traumatic Brain Injury | Phase 2 | Withdrawn | National Institute of Nursing Research (NINR) | 2016-10-06 | 2019-11-19 | |
| Tesamorelin Effects on Liver Fat and Histology in HIV tesamorelin, Placebo - Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD) | Not applicable | Completed | Massachusetts General Hospital | 61 | 2015-07-01 | 2020-01-27 |
| Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue Tesamorelin, Placebo - Abdominal Obesity | Not applicable | Withdrawn | Massachusetts General Hospital | 2014-01-01 | 2014-01-24 | |
| Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Tesamorelin for injection - HIV | Terminated | Theratechnologies | 391 | 2013-02-01 | 2018-09-11 | |
| Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® Tesamorelin, Placebo-Control - Diabetic Retinopathy, HIV | Phase 4 | Terminated | Theratechnologies | 129 | 2012-06-01 | 2018-09-11 |
| Egrifta Replacement and Sleep Disordered Breathing Tesamorelin (Egrifta) - Lipodystrophy | Withdrawn | Johns Hopkins University | 2012-05-01 | 2017-03-03 | ||
| Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting Tesamorelin, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Terminated | Theratechnologies | 3 | 2011-09-01 | 2022-03-18 |
| Effects of Growth Hormone Releasing Hormone in HIV tesamorelin, placebo - HIV, HIV Lipodystrophy | Not applicable | Completed | Massachusetts General Hospital | 54 | 2010-12-01 | 2017-10-30 |
| Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men Growth Hormone Releasing Hormone (Tesamorelin) - Healthy Volunteers | Not applicable | Completed | Massachusetts General Hospital | 15 | 2009-02-01 | 2011-04-19 |
| Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Growth hormone releasing hormone (GHRH) 1-44, Placebo - Abdominal Obesity, Growth Hormone Deficiency | Phase 2 | Completed | Massachusetts General Hospital | 60 | 2008-07-01 | 2017-12-13 |
| Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients Tesamorelin - HIV | Phase 1 | Completed | Theratechnologies | 18 | 2008-05-01 | 2013-12-16 |
| TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy Tesamorelin, Placebo for Tesamorelin - Lipodystrophy, HIV Infections | Phase 3 | Completed | Theratechnologies | 263 | 2007-08-01 | 2022-09-30 |
| TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 - HIV Infections, Lipodystrophy | Phase 3 | Completed | Theratechnologies | 412 | 2005-06-01 | 2013-11-27 |
Showing 20 of 21. Sign in to see all of them.
Lipodystrophy (4) · Obesity, Abdominal (4) · Non-alcoholic Fatty Liver Disease (3) · Cognitive Dysfunction (2) · Dwarfism, Pituitary (2) · Fatty Liver (2) · HIV Infections (2) · HIV-Associated Lipodystrophy Syndrome (2) · Acquired Immunodeficiency Syndrome (1) · Brain Injuries, Traumatic (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Retinopathy (1) · Fibrosis (1) · Frailty (1) · Muscular Atrophy (1)
Massachusetts General Hospital (7) · Theratechnologies (7) · Johns Hopkins University (2) · Columbia University (1) · Hudson Biotech (1) · National Institute of Nursing Research (NINR) (1) · The University of Texas Medical Branch, Galveston (1) · University of California, San Diego (1)
United States (16) · Canada (3) · Belgium (1) · China (1) · France (1) · Spain (1) · United Kingdom (1)
Steven Grinspoon, MD (4) · Fred Sattler, MD (1) · Jean-Claude Mamputu, PhD (1) · Jessica Gill, Ph.D. (1) · Kristine M. Erlandson, MD (1) · Lindsay T. Fourman, MD (1) · Marilyn De Chantal (1) · Pamela U. Freda, MD (1) · Philip L Smith, M.D. (1) · Randall J Urban, MD (1) · Richard Casaburi, PhD, MD (1) · Richard Larouche, MD (1) · Ronald J Ellis, MD, PhD (1) · Sami Tuffaha, MD (1) · Steven K Grinspoon, M.D. (1)
PMID 20101189, PMID 20554713, PMID 22495074, PMID 28832410, PMID 18057338, PMID 20943777, PMID 21531600, PMID 23015655, PMID 24178787, PMID 24291224, PMID 25038357, PMID 28617838, PMID 29031905, PMID 31611038, PMID 33125080, PMID 33852720, PMID 34006921, PMID 42382101, PMID 42419889
R01DK063639 (1), R01DK110771 (1), R01HL085268 (1), U01AI115711 (1)